Sign inJoin waitlistJoin the waitlist

Roy Kim

Associate Professor of Pediatrics and Head · Children's Hospital of Philadelphia

Credentials: · · · · · · ·

History

Pediatrics and Head Division · Children's Hospital of Philadelphia
Present
Children's Hospital of Philadelphia
Present

Pediatric Endocrinology
Children's Hospital of Philadelphia
2002–2005
Cleveland Clinic
1999–2002
University of North Carolina-Gillings School of Global Public Health
University of North Carolina at Chapel Hill School of Medicine
1993–1997
Pomona College
1988–1992

Research

Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway
Journal of Biological Chemistry · 2009 · 200 citations
Nutritional supplementation with trans-10, cis-12-conjugated linoleic acid induces inflammation of white adipose tissue
Diabetes · 2006 · 132 citations
Retinol saturase promotes adipogenesis and is downregulated in obesity
Proceedings of the National Academy of Sciences of the United States of America · 2009 · 76 citations

Mitchell Lazar
4 papers
Rachana Shah
3 papers · 3 as a fellow
TM
Thomas Moshang
3 papers
Adda Grimberg
2 papers
AD
Andrew Dancis
2 papers
Brooke Sweeney
2 papers
Muredach Reilly
2 papers
Richard Rutstein
2 papers
Alaina Vidmar
1 paper
Amy Christison
1 paper
Ana Cristancho
1 paper
AJ
Anna Janss
1 paper

Grants

Effects of Recombinant IGF-I in HIV Associated Metabolic Disease
National Institute of Diabetes and Digestive and Kidney Diseases · K23
Contact PI · $440.3K · Ut Southwestern Medical Center
2009–2013
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $6.5K · Children's Hosp of Philadelphia
2005–2006

Clinical trials

Effects of IGF-I in HIV Metabolic Disease
Principal investigator · Terminated · Phase 1
University of Texas Southwestern Medical Center
2011–2013
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
Site PI · Not yet recruiting · Phase 3
Eli Lilly and Company
2026–2032
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2027
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2024–2027